Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

24
5 Cheap Chinese Stocks to Buy Now

2018-07-05 investorplace
With trade war fears plaguing the market, Chinese stocks have been receiving some bad rap recently. But don’t let this distract you. The top China-based stocks present stellar investing opportunities. And you don’t just have to take my word for it. Here we use TipRanks to pinpoint the best Chinese stocks according to the Street. This website tracks the latest ratings from over 4,800 analysts — so we can find the most highly-rated stocks with just a couple of clicks.
WFC WFCNP WFC.WS F WFC.PRL WFC.PRJ WFC.PRT WB BABA WFC.PRR WFC.PRQ SINA WFC.PRP WFC.PRO WFC.PRN 0700 BGNE WFC.PRY WFC.PRX BIDU WFC.PRW WFC.PRV

2
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2018-07-03 globenewswire
CAMBRIDGE, Mass., and BEIJING, China, July 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on June 29, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 40,608 American Depositary Shares to 85 new employees under BeiGene’s 2018 Inducement Equity Plan.
CELGZ CELG BGNE

58
3 Things In Biotech, June 30: Aptose Gets Rolling Again; Tesaro Heads To China; Alexion Goes Big Across The Pond

2018-06-30 seekingalpha
Hello all, and welcome to another edition of 3 Things in Biotech. Today, I'm going to do something a little extra for you. I'm offering a sneak peek into what members of the Total Pharma Tracker get every day. If you like what you see and would like to get more ideas like this each day, consider becoming a subscriber!
TSRO AZN AZN BGNE

73
Mirati Therapeutics: How Much Higher Can This 'Rocket' Go?

2018-06-21 seekingalpha
The shares of small oncology concern Mirati Therapeutics have shot past $50 recently, less than a year after we first recommended the equity at $5.
MRTX BGNE

182
Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data

2018-06-18 seekingalpha
Selecta Biopharma (SELB) recently presented more data from Phase 2 clinical trial of its lead candidate SEL-212 (SVP-Rapamycin + pegsiticase) in chronic severe gout. In this trial 27 patients were inducted. 81% of the patient group had a clearly marked lower level of uric acid after three months of drug administration. This extended data is a definite improvement over data from earlier Phase 2 data in which 19 patients were evaluated and 75% of them had a clearly low level of uric acid after a similar 3-month duration.
BLUE KPTI TEVA EPZM TEVVF WM GBT XLRN ATRA RDY TEVJF BGNE BLUE

11
BGNE / BeiGene, Ltd. FORM 8-K (Current Report)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
BGNE

12
BGNE / BeiGene, Ltd. S-8

2018-06-08 sec.gov
As filed with the U.S. Securities and Exchange Commission on June 8, 2018 Registration No. 333- <
BGNE

8
BGNE / BeiGene, Ltd. 8-K (Current Report)

2018-06-08 sec.gov
UNITED STATES
BGNE

64
BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

2018-06-06 globenewswire
CAMBRIDGE, Mass., and BEIJING, China, June 06, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.
CELGZ CELG BGNE

86
China weighs new high-tech stock venue in battle with Hong Kong, people say

2018-06-05 scmp
China is expanding efforts to keep its most promising companies from going public in Hong Kong or the US, with officials studying a new trading venue in Shanghai that would have lower thresholds for biotechnology and high-tech firms, people with knowledge of the matter said.
HNCMF BABA ZLAB BGNE HCM HCM IQV

480
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high.
ECYT AVXS GTHX LOXO ARNA ATRA IMMU BIIB CELG HRTX ADAP REGN AMGN GILD NBIX CRSP SRPT ARIA SUPN SNY CBIO JNJ MRTX NVS BGNE IRR CLSD PFE

30
Week In Review: Fosun In $2 Billion Bidding War For U.S. Rights To Novartis' Generic Drugs

2018-05-20 seekingalpha
Fosun Pharma (SHA: 600196; HK: 02196) is one of the finalists in a $2 billion bidding war to acquire part of Novartis' (NYSE:NVS) US portfolio of generic drugs. Novartis is auctioning off US rights to lower-margined members of its Sandoz generic portfolio while it keeps the more profitable generics. India's Aurobindo, US-based Apollo Global Management and CVC Capital Partners, a Europe-Asia PE firm, have also been asked to submit final offers.
ADOCF KTOV BGNE NVS WXXWY

9
BGNE / BeiGene, Ltd. FORM 8-K (Current Report)

2018-05-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
BGNE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 07725L102